NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development – Yahoo Finance

Oct. 4, 2011 (GLOBE NEWSWIRE) — NovaBay(R) Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide(R) compounds for the local, non-systemic, treatment and prevention of …